全球甲状腺疾病治疗市场规模、份额、趋势和成长分析报告（2026-2034年）

预计甲状腺疾病治疗市场将从 2025 年的 28.5 亿美元成长到 2034 年的 40.1 亿美元，2026 年至 2034 年的复合年增长率为 3.87%。

由于全球甲状腺甲状腺机能低下症、甲状腺功能亢进症和甲状腺癌的盛行率不断上升，全球甲状腺疾病治疗市场正经历稳定成长。人们对早期诊断和定期筛检项目的日益重视推动了市场扩张。碘缺乏症和自体免疫疾病（如桥本氏甲状腺炎和葛瑞夫兹氏病）发病率的增加进一步刺激了治疗需求。医疗服务可近性的提高和学名药的普及也促进了市场成长。

成长要素包括老年人口不断增加，而老年人罹患甲状腺功能障碍的风险较高；以及诊断技术的进步。荷尔蒙补充疗法和标靶癌症治疗的创新正在改善治疗效果。已开发国家不断上涨的医疗成本和有利的报销政策进一步刺激了市场需求。此外，微创手术在甲状腺疾病治疗中的日益普及也促进了市场的稳定发展。

展望未来，个人化医疗和生物製药治疗可望创造新的成长机会。对标靶治疗的持续研究和药物製剂的改进有望提高患者依从性和治疗效果。新兴经济体由于医疗基础设施的改善，预计将实现更高的成长率。随着全球对内分泌健康意识的不断提高，甲状腺疾病治疗市场有望继续稳步扩张。

目录

第一章：引言

第二章执行摘要

第三章 市场变数、趋势与框架

• 市场谱系展望
• 渗透率和成长前景分析
• 价值链分析
• 法律规范
  • 标准与合规性
  • 监管影响分析
• 市场动态
  • 市场驱动因素
  • 市场限制因素
  • 市场机会
  • 市场挑战
• 波特五力分析
• PESTLE分析

第四章：全球甲状腺疾病治疗市场：依适应症划分

• 市场分析、洞察与预测
• 甲状腺机能低下症
• 甲状腺功能亢进

第五章：全球甲状腺疾病治疗市场：依药物分类

• 市场分析、洞察与预测
• 左甲状腺素
• 三碘甲状腺胺酸
• 丙硫氧嘧啶
• 咪唑类化合物
• 其他的

第六章 全球甲状腺疾病治疗市场：依通路划分

• 市场分析、洞察与预测
• 批发分销
• 零售店
• 网路药房

第七章 全球甲状腺疾病治疗市场：依给药途径划分

• 市场分析、洞察与预测
• 口服
• 静脉注射
• 其他的

第八章 全球甲状腺疾病治疗市场：依地区划分

• 区域分析
• 北美市场分析、洞察与预测
  • 我们
  • 加拿大
  • 墨西哥
• 欧洲市场分析、洞察与预测
  • 英国
  • 法国
  • 德国
  • 义大利
  • 俄罗斯
  • 其他欧洲国家
• 亚太市场分析、洞察与预测
  • 印度
  • 日本
  • 韩国
  • 澳洲
  • 东南亚
  • 其他亚太国家
• 拉丁美洲市场分析、洞察与预测
  • 巴西
  • 阿根廷
  • 秘鲁
  • 智利
  • 其他拉丁美洲国家
• 中东和非洲市场分析、洞察与预测
  • 沙乌地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中东和非洲国家

第九章 竞争情势

• 最新趋势
• 公司分类
• 供应链和销售管道合作伙伴（根据现有资讯）
• 市场占有率和市场定位分析（基于现有资讯）
• 供应商情况（基于现有资讯）
• 策略规划

第十章：公司简介

• 主要公司的市占率分析
• 公司简介
  • AbbVie Inc
  • Amgen Inc
  • GlaxoSmithKline Plc
  • Merck KGaA
  • Viatris Inc
  • Novartis AG
  • Pfizer Inc
  • Takeda Pharmaceutical Company Limited
  • Elexis Inc
  • IBSA Institut Biochimique SA（IBSA Group）

The Thyroid Gland Disorder Treatment Market size is expected to reach USD 4.01 Billion in 2034 from USD 2.85 Billion (2025) growing at a CAGR of 3.87% during 2026-2034.

The Global Thyroid Gland Disorder Treatment Market is witnessing steady growth due to the rising prevalence of hypothyroidism, hyperthyroidism, and thyroid cancer worldwide. Increasing awareness about early diagnosis and routine screening programs is supporting market expansion. Growing incidences of iodine deficiency and autoimmune disorders such as Hashimoto's thyroiditis and Graves' disease further drive treatment demand. Improved access to healthcare services and availability of generic medications are also contributing to market growth.

Key drivers include the aging population, which is more prone to thyroid dysfunction, and advancements in diagnostic technologies. Pharmaceutical innovations in hormone replacement therapies and targeted cancer treatments enhance treatment outcomes. Rising healthcare expenditure and favorable reimbursement policies in developed nations further stimulate demand. Additionally, increasing adoption of minimally invasive surgical procedures for thyroid disorders supports the market's steady development.

Looking ahead, personalized medicine and biologic therapies are expected to create new growth opportunities. Continuous research in targeted therapies and improved drug formulations will enhance patient compliance and efficacy. Emerging economies are projected to witness higher growth due to improving healthcare infrastructure. As awareness about endocrine health increases globally, the thyroid gland disorder treatment market is likely to expand consistently.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Indication

• Hypothyroidism
• Hyperthyroidism

By Drug

• Levothyroxine
• Liothyronine
• Propylthiouracil
• Imidazole-based Compounds
• Others

By Distribution Channel

• Wholesale Distribution
• Retail Stores
• Online Pharmacy

By Route of Administration

• Oral
• Intravenous
• Others

COMPANIES PROFILED

• AbbVie Inc, Amgen Inc, GlaxoSmithKline plc, Merck KGaA, Viatris Inc, Novartis AG, Pfizer Inc, Takeda Pharmaceutical Company Limited, Elexis Inc, IBSA Institut Biochimique SA IBSA Group
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL THYROID GLAND DISORDER TREATMENT MARKET: BY INDICATION 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Indication
• 4.2. Hypothyroidism Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Hyperthyroidism Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL THYROID GLAND DISORDER TREATMENT MARKET: BY DRUG 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Drug
• 5.2. Levothyroxine Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Liothyronine Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Propylthiouracil Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Imidazole-based Compounds Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.6. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL THYROID GLAND DISORDER TREATMENT MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Distribution Channel
• 6.2. Wholesale Distribution Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Retail Stores Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Online Pharmacy Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL THYROID GLAND DISORDER TREATMENT MARKET: BY ROUTE OF ADMINISTRATION 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast Route Of Administration
• 7.2. Oral Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Intravenous Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL THYROID GLAND DISORDER TREATMENT MARKET: BY REGION 2022-2034(USD MN)

• 8.1. Regional Outlook
• 8.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.2.1 By Indication
  • 8.2.2 By Drug
  • 8.2.3 By Distribution Channel
  • 8.2.4 By Route Of Administration
  • 8.2.5 United States
  • 8.2.6 Canada
  • 8.2.7 Mexico
• 8.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.3.1 By Indication
  • 8.3.2 By Drug
  • 8.3.3 By Distribution Channel
  • 8.3.4 By Route Of Administration
  • 8.3.5 United Kingdom
  • 8.3.6 France
  • 8.3.7 Germany
  • 8.3.8 Italy
  • 8.3.9 Russia
  • 8.3.10 Rest Of Europe
• 8.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.4.1 By Indication
  • 8.4.2 By Drug
  • 8.4.3 By Distribution Channel
  • 8.4.4 By Route Of Administration
  • 8.4.5 India
  • 8.4.6 Japan
  • 8.4.7 South Korea
  • 8.4.8 Australia
  • 8.4.9 South East Asia
  • 8.4.10 Rest Of Asia Pacific
• 8.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.5.1 By Indication
  • 8.5.2 By Drug
  • 8.5.3 By Distribution Channel
  • 8.5.4 By Route Of Administration
  • 8.5.5 Brazil
  • 8.5.6 Argentina
  • 8.5.7 Peru
  • 8.5.8 Chile
  • 8.5.9 South East Asia
  • 8.5.10 Rest of Latin America
• 8.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.6.1 By Indication
  • 8.6.2 By Drug
  • 8.6.3 By Distribution Channel
  • 8.6.4 By Route Of Administration
  • 8.6.5 Saudi Arabia
  • 8.6.6 UAE
  • 8.6.7 Israel
  • 8.6.8 South Africa
  • 8.6.9 Rest of the Middle East And Africa

Chapter 9. COMPETITIVE LANDSCAPE

• 9.1. Recent Developments
• 9.2. Company Categorization
• 9.3. Supply Chain & Channel Partners (based on availability)
• 9.4. Market Share & Positioning Analysis (based on availability)
• 9.5. Vendor Landscape (based on availability)
• 9.6. Strategy Mapping

Chapter 10. COMPANY PROFILES OF GLOBAL THYROID GLAND DISORDER TREATMENT INDUSTRY

• 10.1. Top Companies Market Share Analysis
• 10.2. Company Profiles
  • 10.2.1 AbbVie Inc
  • 10.2.2 Amgen Inc
  • 10.2.3 GlaxoSmithKline Plc
  • 10.2.4 Merck KGaA
  • 10.2.5 Viatris Inc
  • 10.2.6 Novartis AG
  • 10.2.7 Pfizer Inc
  • 10.2.8 Takeda Pharmaceutical Company Limited
  • 10.2.9 Elexis Inc
  • 10.2.10 IBSA Institut Biochimique SA (IBSA Group)